Viatris Inc. · NASDAQ:VTRS
Viatris — Mylan — Merger or Acquisition (July 2014)
5 slides from Viatris's merger presentation, Jul 14, 2014
Slide 1: Abbott-Mylan Transaction Overview
Abbott-Mylan Transaction Overview
Slide 2: Strategic Rationale
Strategic Rationale Abbott continues to actively manage and shape its portfolio for long-term, durable growth as business segments, economies and geographies evolve Abbott will sell its developed markets branded generics pharmaceuticals business to Mylan for a value of ~$5.3 billion based on Mylan’s
Slide 3: Abbott's Branded Generics Business in Developed Markets Going to Mylan
Abbott’s Branded Generics Business in Developed Markets Going to Mylan Company Confidential © 2014 Abbott Sales of ~$2 billion in 2013 ~3,800 employees Presence in 40+ countries primarily in Europe plus Japan, Canada, Australia and New Zealand Portfolio of 100+ branded generic and specialty products
Slide 4: Abbott's Branded Generics Business in 2015
Abbott’s Branded Generics Business in 2015 Company Confidential © 2014 Abbott Leading presence in emerging geographies No. 1 in India, Chile, Colombia and Peru; top 10 in Russia Strong expertise and broad portfolios in Gastroenterology, Women’s Health, CNS/Pain, Cardio and Respiratory Sales of nearl
Slide 5: Cautionary Statements Regarding Forward-Looking Information
Cautionary Statements Regarding Forward-Looking Information Company Confidential © 2014 Abbott This communication contains forward-looking statements that are based on management’s current expectations, estimates and projections. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,